congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Pexidartinib
CTOS 2023 | November 1-4, 2023
A phase 3 study of the efficacy and safety of pexidartinib in Asian patients with tenosynovial giant cell tumor
Oral
Pexidartinib
CTOS 2023 | November 1-4, 2023
A phase 4, multicenter, global clinical trial to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
Poster
Pexidartinib
CTOS 2023 | November 1-4, 2023
Epidemiology of tenosynovial giant cell tumor in the United States
Poster
Pexidartinib
CTOS 2023 | November 1-4, 2023
Patient-reported continued benefits in patients treated with pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States
Poster
Pexidartinib
CTOS 2023 | November 1-4, 2023
Pexidartinib risk evaluation and mitigation strategy program: 3-year safety data assessment